Device data
Health topic HIV/AIDS
Classification Treatment
Scope Clinical trial
Manufacturer
location
California, United States

The Hemopurifier™ has been developed to address the treatment of drug and vaccine-resistant pathogens, including Ebola & HIV which causes AIDS.

Detailed description of the solution

The Hemopurifier™ is a dialysis-type medical device designed to mimic the natural immune response of clearing infectious viruses and toxins before the occurrence of cell and organ infection. Human in-vitro blood studies have documented a rapid capture of circulating HIV and gp120, a toxic surface protein known to deplete the immune T-cells required to fight off infection. If commercialized, the Hemopurifier™ would represent the first medical device enlisted as a treatment for HIV/AIDS.

Designed by

When and where it was tested/implemented

Testing has been done in the United States since 2001. It is currently being tested in human clinical trials in India.

Funding Source

Private Funding

References

Peer-reviewed publication

Duffin, R.P. & Tullis, R.H. (2002). Mathematical models that predict the complete course of HIV infection and AIDS. J. Theor. Med, 4(3), 157-166.

Tullis, R.H., Ambrus, J.L. & Joyce, J.A. (2001). Affinity Hemodialysis as a Treatment for AIDS. American Clinical Laboratories, Oct/Nov, 22-23.

Tullis, R.H., Duffin, R.P., Zech, M. & Ambrus, J.L. (2001). Affinity Hemodialysis for Antiviral Therapy. I. Removal of HIV-1 from Cell Culture Supernatants, Plasma and Blood. Therapeutic Apheresis, 6 (3), 213-220.

Tullis, R.H., Scammura, D.O. & Ambrus, J.L. (2002). Affinity Hemodialysis for Antiviral Therapy with Specific Application to HIV. J. Theor Med, 3(2002), 157-166.

Tullis, R.H., Duffin, R.P., Zech, M. & Ambrus, J.L. (2003). Affinity hemodialysis for antiviral therapy. II. Removal of HIV-1 viral proteins from cell culture supernatants and whole blood. Blood Purification, 21(1), 58-64.

Approval by regulatory bodies or standards boards

An investigational device exemption (IDE) to initiate clinical studies in the United States is pending with the Food and Drug Administration.

Page data
SDG SDG03 Good health and well-being, SDG09 Industry innovation and infrastructure
Authors Lonny Grafman, Chris Waterguy, Emilio, Kathleen Sienko, Amir Sabet Sarvestani
License CC-BY-SA-3.0
Organizations Appropedia Foundation, University of Michigan
Language English (en)
Related 0 subpages, 1 pages link here
Redirects Hemopurifier
Views 537 page views (analytics)
Created January 13, 2012 by Evashiu
Last edit September 10, 2026 by Felipe Schenone